The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Open accessAbstract
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations 1,2 . RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS and NRAS, with affinity for both mutant and wild-type variants 3 . More than 90% of cases of human pancreatic ductal adenocarcinoma (PDAC) are driven by activating mutations in KRAS 4 . Here we assessed the therapeutic potential of RMC-7977 in a comprehensive range of PDAC models. We observed broad and pronounced anti-tumour activity across models following direct RAS inhibition at exposures that were well-tolerated in vivo. Pharmacological analyses revealed divergent responses to RMC-7977 in tumour versus normal tissues. Treated tumours exhibited waves of apoptosis along with sustained proliferative arrest, whereas normal tissues underwent only transient decreases in proliferation, with no evidence of apoptosis. In the autochthonous KPC mouse model, RMC-7977 treatment resulted in a profound extension of survival followed by on-treatment relapse. Analysis of relapsed tumours identified Myc copy number gain as a prevalent candidate resistance mechanism, which could be overcome by combinatorial TEAD inhibition in vitro. Together, these data establish a strong preclinical rationale for the use of broad-spectrum RAS-GTP inhibition in the setting of PDAC and identify a promising candidate combination therapeutic regimen to overcome monotherapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently developed “pan-RAS” or “pan-KRAS” inhibitors capable of targeting all RAS isoforms or all KRAS alleles will be broadly applicable to most patients with PDAC (71–74).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [74]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“56.2) 63 .”
InfluentialCox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594 · cited 1×
“Read counts were subsequently corrected for GC content using LOWESS smoothing algorithm, normalized and segmented using circular binary segmentation 57,58 .”
MethodAdjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., & Mann, M. (2011) · Journal of Proteome Research · doi:10.1021/pr101065j · Cited by 5,500 · cited 2×
“All mass spectrometry raw files were jointly searched using MaxQuant 60 (MQ) 2.4.3.0 Androm-eda search engine 61 using the UniProt Mouse Reference Proteome 62 (21,864 sequences, accessed October 2023) and known contaminants included in MQ.”
BackgroundMethodInfluentialMapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt
Durinck, S., Spellman, P. T., Birney, E., & Huber, W. (2009) · Nature Protocols · doi:10.1038/nprot.2009.97 · Cited by 4,197
Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences
Soneson, C., Love, M. I., & Robinson, M. D. (2015) · F1000Research · doi:10.12688/f1000research.7563.1 · Cited by 3,929 · cited 2×
“The PLATE-Seq FASTQ files were pseudoaligned to the GRCh38 human transcriptome and gene expression was quantified using kallisto (version 0.44.0), tximport package 50 and biomaRt package 65 .”
MethodInfluentialNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394 · cited 1×
“Gene mutation, gene expression and lineage data were downloaded from the 22Q4 release of the DepMap Data Portal 45 .”
Method
Cited by
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“Recently developed “pan-RAS” or “pan-KRAS” inhibitors capable of targeting all RAS isoforms or all KRAS alleles will be broadly applicable to most patients with PDAC (71–74).”
BackgroundSelf-citationKRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Self-citationRAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 145
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2505783 · Cited by 90
Self-citation
Metadata
- Authors
- Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., Drizyte-Miller, K., Menard, M., Dilly, J., Sastra, S. A., Palermo, C. F., Hasselluhn, M. C., Decker-Farrell, A. R., Chang, S., Jiang, L., Wei, X., Yang, Y. C., Helland, C., Courtney, H., Gindin, Y., Muonio, K., Zhao, R., Kemp, S. B., Clendenin, C., Sor, R., Vostrejs, W. P., Hibshman, P. S., Amparo, A. M., Hennessey, C., Rees, M. G., Ronan, M. M., Roth, J. A., Brodbeck, J., Tomassoni, L., Bakir, B., Socci, N. D., Herring, L. E., Barker, N. K., Wang, J., Cleary, J. M., Wolpin, B. M., Chabot, J. A., Kluger, M. D., Manji, G. A., Tsai, K. Y., Sekulic, M., Lagana, S. M., Califano, A., Quintana, E., Wang, Z., Smith, J. A. M., Holderfield, M., Wildes, D., Lowe, S. W., Badgley, M. A., Aguirre, A. J., Vonderheide, R. H., Stanger, B. Z., Baslan, T., Der, C. J., Singh, M., & Olive, K. P.
- Affiliations
- Columbia University Irving Medical Center (US)
- Revolution Medicines (United States) (US)
- University of North Carolina at Chapel Hill (US)
- University of Pennsylvania (US)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Abramson Cancer Center (US)
- Broad Institute (US)
- Moffitt Cancer Center (US)
- Johns Hopkins University (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Singh, Mallika
- Olive, Kenneth P.
- ORCID
- Wasko, Urszula N.
- Jiang, Jingjing
- Dalton, Tanner C.
- Curiel-Garcia, Alvaro
- Edwards, A. Cole
- Wang, Yingyun
- Lee, Bianca
- Orlen, Margo
- Tian, Sha
- Stalnecker, Clint A.
- Menard, Marie
- Dilly, Julien
- Sastra, Stephen A.
- Palermo, Carmine F.
- Hasselluhn, Marie C.
- Decker-Farrell, Amanda R.
- Chang, Stephanie
- Jiang, Lingyan
- Yang, Yu C.
- Helland, Ciara
- Gindin, Yevgeniy
- Kemp, Samantha B.
- Clendenin, Cynthia
- Sor, Rina
- Vostrejs, William P.
- Hibshman, Priya S.
- Amparo, Amber M.
- Hennessey, Connor
- Rees, Matthew G.
- Ronan, Melissa M.
- Roth, Jennifer A.
- Brodbeck, Jens
- Tomassoni, Lorenzo
- Socci, Nicholas D.
- Herring, Laura E.
- Barker, Natalie K.
- Wang, Junning
- Cleary, James M.
- Wolpin, Brian M.
- Kluger, Michael D.
- Manji, Gulam A.
- Tsai, Kenneth Y.
- Sekulic, Miroslav
- Lagana, Stephen M.
- Califano, Andrea
- Quintana, Elsa
- Wang, Zhengping
- Smith, Jacqueline A. M.
- Holderfield, Matthew
- Wildes, David
- Lowe, Scott W.
- Badgley, Michael A.
- Aguirre, Andrew J.
- Vonderheide, Robert H.
- Stanger, Ben Z.
- Baslan, Timour
- Der, Channing J.
- Singh, Mallika
- Olive, Kenneth P.
- Venue
- Nature
- Published
- 2024-04-08
- Volume
- 629
- Issue
- 8013
- Pages
- 927-936
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC11111406
- OpenAlex
- W4394580205
- Semantic Scholar
- 7776743bf12cbb5f73496d61b0d8b283e856ab6b
- Cited by
- 209
- References
- 64
- Citations by year
- 2026: 78 · 2025: 92 · 2024: 38
- FWCI
- 35.43
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-11-12)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense
- American Cancer Society
- Pancreatic Cancer Action Network
- Lustgarten Foundation
- National Institutes of Health (1s10od021764-01, 1s10od032433-01a1, 1s10od012351-01, UL1TR001873)
- National Cancer Institute (T32CA009140, R01CA229803, P01CA129243, R35CA232113, T32CA009156, F31CA275260, F32CA232529, U01CA217858, P30CA008748, U01CA274312, U01CA272610, R01CA215607, P50CA257911, R01CA266558, U54CA274506, R01CA276268, P30CA016086, P30CA013696, T32CA071341)
- National Institute of General Medical Sciences (T32GM119999)
- National Institute of Allergy and Infectious Diseases (K08AI106953)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK132710)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RMC-7977, pancreatic ductal adenocarcinoma, KRAS mutation, apoptosis, proliferative arrest, KPC mouse model, resistance mechanisms, combination therapy, antitumour activity
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Female, Guanosine Triphosphate, Humans, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Mutation, Neoplasm Recurrence, Local, Pancreatic Neoplasms, Genes, myc, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Apoptosis, Drug Resistance, Neoplasm, GTP Phosphohydrolases, Carcinoma, Pancreatic Ductal, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41586-024-07379-z
- The paper
- Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., Drizyte-Miller, K., Menard, M., Dilly, J., Sastra, S. A., Palermo, C. F., Hasselluhn, M. C., Decker-Farrell, A. R., Chang, S., Jiang, L., . . . Olive, K. P. (2024). Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. https://doi.org/10.1038/s41586-024-07379-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.